Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 21 - You Need To See This

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

UK regulator approves second Alzheimer's drug in months but government won't pay for it

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

The Independent UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

UK's weight loss jab Mounjaro might help people get back to work: All about it

The UK government has announced a novel initiative trial to offer weight loss medication Mounjaro to people with obesity who are unemployed, to improve their health and help them re-enter the workforce, said British Health Minister Wes Streeting said on Tuesday. The trial is part of a broader NHS strategy…

The Times of India

3 Healthcare Stocks That Can Thrive in Any Economy

The healthcare market shows promise due to heightened demand for quality care, technological advancements, preventive measures, and increased public investment, ensuring resilience in any economic condition. Therefore, investors could now consider top healthcare stocks, such as Eli Lilly (LLY), Merck & Co. (MRK), and Abbott Laboratories (ABT). Keep reading.

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The Conversation

inkl

Read news from The Economist, FT, and more,
with one subscription

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.

The Conversation

This Weight-Loss Stock Just Scored a New Street-High Price Target

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read…

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Analysts say market forces will lower cost of obesity drugs - Roll Call

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Snag This Biotech Stock Before November, Here's Why

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly's Eczema Drug Gets FDA Approval, Injectable Treatment Available Within Weeks

The new injectable drug, Lebrikizumab, branded as Ebglyss, is approved for treating atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

International Business Times

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

Get all your
news in one place.

100's of premium titles.
One news app.

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

International Business Times

Key Ingredient In Weight Loss Drugs Ozempic And Wegovy Cuts Risk Of COVID Death: Report

People being treated with the drugs, which both contain semaglutide, had a 33% lower risk of dying from the disease, study found

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

International Business Times

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

The Times of India

Weight loss drug Tirzepatide cuts diabetes risk by an astonishing 94%, says study

A new study on the popular weight loss drug Tirzepatide, manufactured by American pharmaceutical company Eli Lilly, has found the drug could dramatically cut the risk of developing type 2 diabetes in obese or overweight people with prediabetes, compared with a placebo.

Tirzepatide Cuts Diabetes Risk By 94% In Prediabetic, Obese Individuals: Trial Results

The three-year trial results revealed that a once-a-week tirzepatide injection for adults who are prediabetic, obese, or overweight reduced their risk of progressing to type 2 diabetes by 94%.

Stocks Finish Lower as Chip and Energy Stocks Decline

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.24%. US stocks Tuesday gave up an early advance and posted modest losses. Weakness in...

1 … 20 21 22 23

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

416,739 stories

148,965 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play